| Journal | BMJ open |
| Study Type | Randomized Trial |
| Population | Human participants |
COPD breathlessness remains undertreated despite optimal bronchodilator therapy, with limited pharmacologic options for refractory dyspnea. This represents the first rigorous randomized trial examining synthetic THC specifically for severe COPD breathlessness in an outpatient setting.
This Danish crossover RCT will enroll 30 patients with severe COPD and persistent breathlessness despite optimal treatment. Participants receive dronabinol versus placebo for 4 weeks each, separated by 2-week washout, with primary endpoint of breathing discomfort on 0-10 numerical rating scale. Secondary measures include lung function, cortisol levels, functional assessments, and quality of life questionnaires. The crossover design helps control for individual variation in this heterogeneous population.
“I’m cautiously optimistic about cannabinoid mechanisms for dyspnea, but we need this data before recommending dronabinol for COPD breathlessness. The respiratory depression concerns with THC in compromised lung function patients make this safety and efficacy question particularly important.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- What is dronabinol and how might it help COPD patients with severe breathlessness?
- Who is eligible for this dronabinol treatment study?
- How is the effectiveness of dronabinol measured in this study?
- What is the study design and how long does treatment last?
- Is this treatment approach supported by existing evidence?
FAQ
What is dronabinol and how might it help COPD patients with severe breathlessness?
Dronabinol is a synthetic form of delta-9-tetrahydrocannabinol (THC), the active component in cannabis. This study investigates whether dronabinol can reduce breathing discomfort in patients with severe COPD who continue to experience persistent breathlessness despite receiving optimal conventional treatment.
Who is eligible for this dronabinol treatment study?
Patients aged 18 years or older with severe or very severe COPD and persistent breathlessness despite optimal treatment are eligible. However, patients with ongoing infections, substance abuse history, or significant comorbidities are excluded from the study.
How is the effectiveness of dronabinol measured in this study?
The primary outcome is breathing discomfort measured using a 0-10 Numerical Rating Scale. Secondary outcomes include lung function tests, quality of life questionnaires, functional assessments, and plasma THC concentrations to comprehensively evaluate treatment effects.
What is the study design and how long does treatment last?
This is a randomized, double-blinded, placebo-controlled crossover trial where patients receive either dronabinol or placebo for 4 weeks, followed by a 2-week washout period, then cross over to the other treatment for another 4 weeks. This design allows each patient to serve as their own control, improving the reliability of results.
Is this treatment approach supported by existing evidence?
While cannabis-based medicines have shown potential for alleviating breathlessness, this study represents important research to establish evidence-based clinical use of dronabinol specifically for severe COPD-related dyspnea. The controlled trial design will provide crucial data on both efficacy and safety in this vulnerable patient population.